nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—ABCB1—ovarian cancer	0.543	1	CbGaD
Naltrexone—ABCB1—Topotecan—ovarian cancer	0.0616	0.354	CbGbCtD
Naltrexone—ABCB1—Vinorelbine—ovarian cancer	0.0434	0.249	CbGbCtD
Naltrexone—ABCB1—Paclitaxel—ovarian cancer	0.0305	0.175	CbGbCtD
Naltrexone—ABCB1—Docetaxel—ovarian cancer	0.0221	0.127	CbGbCtD
Naltrexone—ABCB1—Doxorubicin—ovarian cancer	0.0164	0.0945	CbGbCtD
Naltrexone—Naloxone—TLR4—ovarian cancer	0.00386	0.617	CrCbGaD
Naltrexone—Naloxone—ESR1—ovarian cancer	0.00108	0.173	CrCbGaD
Naltrexone—Buprenorphine—ABCB1—ovarian cancer	0.000464	0.0741	CrCbGaD
Naltrexone—Naloxone—ABCB1—ovarian cancer	0.00046	0.0735	CrCbGaD
Naltrexone—Morphine—ABCB1—ovarian cancer	0.000388	0.0621	CrCbGaD
Naltrexone—Angina pectoris—Epirubicin—ovarian cancer	0.000237	0.000854	CcSEcCtD
Naltrexone—Tachycardia—Paclitaxel—ovarian cancer	0.000236	0.000851	CcSEcCtD
Naltrexone—Skin disorder—Paclitaxel—ovarian cancer	0.000235	0.000847	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000234	0.000845	CcSEcCtD
Naltrexone—Bronchitis—Epirubicin—ovarian cancer	0.000234	0.000843	CcSEcCtD
Naltrexone—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000234	0.000843	CcSEcCtD
Naltrexone—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000232	0.000839	CcSEcCtD
Naltrexone—Anorexia—Paclitaxel—ovarian cancer	0.00023	0.000831	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000229	0.000828	CcSEcCtD
Naltrexone—Vomiting—Vinorelbine—ovarian cancer	0.000228	0.000824	CcSEcCtD
Naltrexone—Rash—Vinorelbine—ovarian cancer	0.000226	0.000817	CcSEcCtD
Naltrexone—Dermatitis—Vinorelbine—ovarian cancer	0.000226	0.000816	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000226	0.000815	CcSEcCtD
Naltrexone—Headache—Vinorelbine—ovarian cancer	0.000225	0.000812	CcSEcCtD
Naltrexone—Syncope—Docetaxel—ovarian cancer	0.000225	0.000812	CcSEcCtD
Naltrexone—Influenza—Doxorubicin—ovarian cancer	0.000225	0.000811	CcSEcCtD
Naltrexone—Palpitations—Docetaxel—ovarian cancer	0.000222	0.0008	CcSEcCtD
Naltrexone—Weight increased—Epirubicin—ovarian cancer	0.000221	0.000798	CcSEcCtD
Naltrexone—Loss of consciousness—Docetaxel—ovarian cancer	0.00022	0.000796	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00022	0.000794	CcSEcCtD
Naltrexone—Weight decreased—Epirubicin—ovarian cancer	0.00022	0.000793	CcSEcCtD
Naltrexone—Cough—Docetaxel—ovarian cancer	0.000219	0.00079	CcSEcCtD
Naltrexone—Angina pectoris—Doxorubicin—ovarian cancer	0.000219	0.00079	CcSEcCtD
Naltrexone—Insomnia—Paclitaxel—ovarian cancer	0.000218	0.000789	CcSEcCtD
Naltrexone—Pneumonia—Epirubicin—ovarian cancer	0.000218	0.000786	CcSEcCtD
Naltrexone—Convulsion—Docetaxel—ovarian cancer	0.000217	0.000784	CcSEcCtD
Naltrexone—Paraesthesia—Paclitaxel—ovarian cancer	0.000217	0.000783	CcSEcCtD
Naltrexone—Hypertension—Docetaxel—ovarian cancer	0.000217	0.000782	CcSEcCtD
Naltrexone—Infestation—Epirubicin—ovarian cancer	0.000217	0.000781	CcSEcCtD
Naltrexone—Infestation NOS—Epirubicin—ovarian cancer	0.000217	0.000781	CcSEcCtD
Naltrexone—Bronchitis—Doxorubicin—ovarian cancer	0.000216	0.00078	CcSEcCtD
Naltrexone—Dyspnoea—Paclitaxel—ovarian cancer	0.000215	0.000777	CcSEcCtD
Naltrexone—Somnolence—Paclitaxel—ovarian cancer	0.000215	0.000775	CcSEcCtD
Naltrexone—Chest pain—Docetaxel—ovarian cancer	0.000214	0.000771	CcSEcCtD
Naltrexone—Myalgia—Docetaxel—ovarian cancer	0.000214	0.000771	CcSEcCtD
Naltrexone—Arthralgia—Docetaxel—ovarian cancer	0.000214	0.000771	CcSEcCtD
Naltrexone—Nausea—Vinorelbine—ovarian cancer	0.000213	0.00077	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000212	0.000766	CcSEcCtD
Naltrexone—Urinary tract infection—Epirubicin—ovarian cancer	0.00021	0.00076	CcSEcCtD
Naltrexone—Conjunctivitis—Epirubicin—ovarian cancer	0.00021	0.00076	CcSEcCtD
Naltrexone—Decreased appetite—Paclitaxel—ovarian cancer	0.00021	0.000758	CcSEcCtD
Naltrexone—Dry mouth—Docetaxel—ovarian cancer	0.000209	0.000754	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000209	0.000754	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000209	0.000753	CcSEcCtD
Naltrexone—Fatigue—Paclitaxel—ovarian cancer	0.000208	0.000752	CcSEcCtD
Naltrexone—Pain—Paclitaxel—ovarian cancer	0.000207	0.000746	CcSEcCtD
Naltrexone—Constipation—Paclitaxel—ovarian cancer	0.000207	0.000746	CcSEcCtD
Naltrexone—Confusional state—Docetaxel—ovarian cancer	0.000206	0.000745	CcSEcCtD
Naltrexone—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000205	0.000739	CcSEcCtD
Naltrexone—Anaphylactic shock—Docetaxel—ovarian cancer	0.000205	0.000739	CcSEcCtD
Naltrexone—Oedema—Docetaxel—ovarian cancer	0.000205	0.000739	CcSEcCtD
Naltrexone—Weight increased—Doxorubicin—ovarian cancer	0.000204	0.000738	CcSEcCtD
Naltrexone—Epistaxis—Epirubicin—ovarian cancer	0.000204	0.000737	CcSEcCtD
Naltrexone—Infection—Docetaxel—ovarian cancer	0.000203	0.000734	CcSEcCtD
Naltrexone—Weight decreased—Doxorubicin—ovarian cancer	0.000203	0.000734	CcSEcCtD
Naltrexone—Sinusitis—Epirubicin—ovarian cancer	0.000203	0.000733	CcSEcCtD
Naltrexone—Pneumonia—Doxorubicin—ovarian cancer	0.000202	0.000727	CcSEcCtD
Naltrexone—Shock—Docetaxel—ovarian cancer	0.000201	0.000727	CcSEcCtD
Naltrexone—Nervous system disorder—Docetaxel—ovarian cancer	0.000201	0.000725	CcSEcCtD
Naltrexone—Infestation NOS—Doxorubicin—ovarian cancer	0.0002	0.000723	CcSEcCtD
Naltrexone—Infestation—Doxorubicin—ovarian cancer	0.0002	0.000723	CcSEcCtD
Naltrexone—Tachycardia—Docetaxel—ovarian cancer	0.0002	0.000721	CcSEcCtD
Naltrexone—Feeling abnormal—Paclitaxel—ovarian cancer	0.000199	0.000718	CcSEcCtD
Naltrexone—Skin disorder—Docetaxel—ovarian cancer	0.000199	0.000718	CcSEcCtD
Naltrexone—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000198	0.000713	CcSEcCtD
Naltrexone—Anorexia—Docetaxel—ovarian cancer	0.000195	0.000704	CcSEcCtD
Naltrexone—Conjunctivitis—Doxorubicin—ovarian cancer	0.000195	0.000703	CcSEcCtD
Naltrexone—Urinary tract infection—Doxorubicin—ovarian cancer	0.000195	0.000703	CcSEcCtD
Naltrexone—Hepatitis—Epirubicin—ovarian cancer	0.000194	0.000702	CcSEcCtD
Naltrexone—Pharyngitis—Epirubicin—ovarian cancer	0.000193	0.000696	CcSEcCtD
Naltrexone—Urticaria—Paclitaxel—ovarian cancer	0.000192	0.000693	CcSEcCtD
Naltrexone—Connective tissue disorder—Epirubicin—ovarian cancer	0.000191	0.000689	CcSEcCtD
Naltrexone—Body temperature increased—Paclitaxel—ovarian cancer	0.000191	0.000689	CcSEcCtD
Naltrexone—Abdominal pain—Paclitaxel—ovarian cancer	0.000191	0.000689	CcSEcCtD
Naltrexone—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000189	0.000684	CcSEcCtD
Naltrexone—Epistaxis—Doxorubicin—ovarian cancer	0.000189	0.000682	CcSEcCtD
Naltrexone—Sinusitis—Doxorubicin—ovarian cancer	0.000188	0.000678	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000187	0.000673	CcSEcCtD
Naltrexone—Insomnia—Docetaxel—ovarian cancer	0.000185	0.000668	CcSEcCtD
Naltrexone—Paraesthesia—Docetaxel—ovarian cancer	0.000184	0.000664	CcSEcCtD
Naltrexone—Dyspnoea—Docetaxel—ovarian cancer	0.000183	0.000659	CcSEcCtD
Naltrexone—Somnolence—Docetaxel—ovarian cancer	0.000182	0.000657	CcSEcCtD
Naltrexone—Eye disorder—Epirubicin—ovarian cancer	0.000182	0.000656	CcSEcCtD
Naltrexone—Tinnitus—Epirubicin—ovarian cancer	0.000181	0.000654	CcSEcCtD
Naltrexone—Cardiac disorder—Epirubicin—ovarian cancer	0.00018	0.000651	CcSEcCtD
Naltrexone—Hepatitis—Doxorubicin—ovarian cancer	0.00018	0.000649	CcSEcCtD
Naltrexone—Pharyngitis—Doxorubicin—ovarian cancer	0.000179	0.000644	CcSEcCtD
Naltrexone—Decreased appetite—Docetaxel—ovarian cancer	0.000178	0.000642	CcSEcCtD
Naltrexone—Hypersensitivity—Paclitaxel—ovarian cancer	0.000178	0.000642	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000177	0.000638	CcSEcCtD
Naltrexone—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000177	0.000638	CcSEcCtD
Naltrexone—Fatigue—Docetaxel—ovarian cancer	0.000177	0.000637	CcSEcCtD
Naltrexone—Angiopathy—Epirubicin—ovarian cancer	0.000176	0.000637	CcSEcCtD
Naltrexone—Immune system disorder—Epirubicin—ovarian cancer	0.000176	0.000634	CcSEcCtD
Naltrexone—Mediastinal disorder—Epirubicin—ovarian cancer	0.000175	0.000632	CcSEcCtD
Naltrexone—Pain—Docetaxel—ovarian cancer	0.000175	0.000632	CcSEcCtD
Naltrexone—Constipation—Docetaxel—ovarian cancer	0.000175	0.000632	CcSEcCtD
Naltrexone—Chills—Epirubicin—ovarian cancer	0.000174	0.000629	CcSEcCtD
Naltrexone—Asthenia—Paclitaxel—ovarian cancer	0.000173	0.000626	CcSEcCtD
Naltrexone—Alopecia—Epirubicin—ovarian cancer	0.000172	0.00062	CcSEcCtD
Naltrexone—Pruritus—Paclitaxel—ovarian cancer	0.000171	0.000617	CcSEcCtD
Naltrexone—Mental disorder—Epirubicin—ovarian cancer	0.00017	0.000615	CcSEcCtD
Naltrexone—Malnutrition—Epirubicin—ovarian cancer	0.000169	0.000611	CcSEcCtD
Naltrexone—Feeling abnormal—Docetaxel—ovarian cancer	0.000169	0.000609	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—ovarian cancer	0.000168	0.000607	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—ovarian cancer	0.000168	0.000605	CcSEcCtD
Naltrexone—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000167	0.000604	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—ovarian cancer	0.000167	0.000602	CcSEcCtD
Naltrexone—Flatulence—Epirubicin—ovarian cancer	0.000167	0.000602	CcSEcCtD
Naltrexone—Tension—Epirubicin—ovarian cancer	0.000166	0.000599	CcSEcCtD
Naltrexone—Dysgeusia—Epirubicin—ovarian cancer	0.000166	0.000598	CcSEcCtD
Naltrexone—Diarrhoea—Paclitaxel—ovarian cancer	0.000165	0.000597	CcSEcCtD
Naltrexone—Nervousness—Epirubicin—ovarian cancer	0.000164	0.000593	CcSEcCtD
Naltrexone—Back pain—Epirubicin—ovarian cancer	0.000164	0.000591	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—ovarian cancer	0.000163	0.000589	CcSEcCtD
Naltrexone—Muscle spasms—Epirubicin—ovarian cancer	0.000163	0.000587	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—ovarian cancer	0.000162	0.000586	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000162	0.000585	CcSEcCtD
Naltrexone—Abdominal pain—Docetaxel—ovarian cancer	0.000162	0.000584	CcSEcCtD
Naltrexone—Body temperature increased—Docetaxel—ovarian cancer	0.000162	0.000584	CcSEcCtD
Naltrexone—Chills—Doxorubicin—ovarian cancer	0.000161	0.000582	CcSEcCtD
Naltrexone—Dizziness—Paclitaxel—ovarian cancer	0.00016	0.000577	CcSEcCtD
Naltrexone—Vision blurred—Epirubicin—ovarian cancer	0.000159	0.000576	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—ovarian cancer	0.000159	0.000574	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—ovarian cancer	0.000158	0.000569	CcSEcCtD
Naltrexone—Ill-defined disorder—Epirubicin—ovarian cancer	0.000157	0.000567	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—ovarian cancer	0.000157	0.000565	CcSEcCtD
Naltrexone—Agitation—Epirubicin—ovarian cancer	0.000156	0.000561	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—ovarian cancer	0.000154	0.000557	CcSEcCtD
Naltrexone—Tension—Doxorubicin—ovarian cancer	0.000154	0.000555	CcSEcCtD
Naltrexone—Vomiting—Paclitaxel—ovarian cancer	0.000154	0.000554	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—ovarian cancer	0.000153	0.000553	CcSEcCtD
Naltrexone—Malaise—Epirubicin—ovarian cancer	0.000153	0.000551	CcSEcCtD
Naltrexone—Rash—Paclitaxel—ovarian cancer	0.000152	0.00055	CcSEcCtD
Naltrexone—Dermatitis—Paclitaxel—ovarian cancer	0.000152	0.000549	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—ovarian cancer	0.000152	0.000549	CcSEcCtD
Naltrexone—Syncope—Epirubicin—ovarian cancer	0.000152	0.000548	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—ovarian cancer	0.000151	0.000547	CcSEcCtD
Naltrexone—Headache—Paclitaxel—ovarian cancer	0.000151	0.000546	CcSEcCtD
Naltrexone—Hypersensitivity—Docetaxel—ovarian cancer	0.000151	0.000544	CcSEcCtD
Naltrexone—Muscle spasms—Doxorubicin—ovarian cancer	0.000151	0.000543	CcSEcCtD
Naltrexone—Palpitations—Epirubicin—ovarian cancer	0.00015	0.00054	CcSEcCtD
Naltrexone—Loss of consciousness—Epirubicin—ovarian cancer	0.000149	0.000537	CcSEcCtD
Naltrexone—Cough—Epirubicin—ovarian cancer	0.000148	0.000533	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—ovarian cancer	0.000148	0.000533	CcSEcCtD
Naltrexone—Asthenia—Docetaxel—ovarian cancer	0.000147	0.00053	CcSEcCtD
Naltrexone—Convulsion—Epirubicin—ovarian cancer	0.000147	0.000529	CcSEcCtD
Naltrexone—Hypertension—Epirubicin—ovarian cancer	0.000146	0.000527	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000145	0.000524	CcSEcCtD
Naltrexone—Pruritus—Docetaxel—ovarian cancer	0.000145	0.000523	CcSEcCtD
Naltrexone—Myalgia—Epirubicin—ovarian cancer	0.000144	0.00052	CcSEcCtD
Naltrexone—Arthralgia—Epirubicin—ovarian cancer	0.000144	0.00052	CcSEcCtD
Naltrexone—Chest pain—Epirubicin—ovarian cancer	0.000144	0.00052	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—ovarian cancer	0.000144	0.000519	CcSEcCtD
Naltrexone—Anxiety—Epirubicin—ovarian cancer	0.000144	0.000518	CcSEcCtD
Naltrexone—Nausea—Paclitaxel—ovarian cancer	0.000143	0.000518	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000143	0.000516	CcSEcCtD
Naltrexone—Discomfort—Epirubicin—ovarian cancer	0.000142	0.000514	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—ovarian cancer	0.000141	0.00051	CcSEcCtD
Naltrexone—Dry mouth—Epirubicin—ovarian cancer	0.000141	0.000508	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—ovarian cancer	0.00014	0.000507	CcSEcCtD
Naltrexone—Diarrhoea—Docetaxel—ovarian cancer	0.00014	0.000506	CcSEcCtD
Naltrexone—Confusional state—Epirubicin—ovarian cancer	0.000139	0.000503	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—ovarian cancer	0.000138	0.000499	CcSEcCtD
Naltrexone—Oedema—Epirubicin—ovarian cancer	0.000138	0.000498	CcSEcCtD
Naltrexone—Anaphylactic shock—Epirubicin—ovarian cancer	0.000138	0.000498	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—ovarian cancer	0.000138	0.000497	CcSEcCtD
Naltrexone—Infection—Epirubicin—ovarian cancer	0.000137	0.000495	CcSEcCtD
Naltrexone—Cough—Doxorubicin—ovarian cancer	0.000137	0.000493	CcSEcCtD
Naltrexone—Shock—Epirubicin—ovarian cancer	0.000136	0.00049	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—ovarian cancer	0.000136	0.00049	CcSEcCtD
Naltrexone—Nervous system disorder—Epirubicin—ovarian cancer	0.000135	0.000489	CcSEcCtD
Naltrexone—Dizziness—Docetaxel—ovarian cancer	0.000135	0.000489	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—ovarian cancer	0.000135	0.000488	CcSEcCtD
Naltrexone—Tachycardia—Epirubicin—ovarian cancer	0.000135	0.000486	CcSEcCtD
Naltrexone—Skin disorder—Epirubicin—ovarian cancer	0.000134	0.000484	CcSEcCtD
Naltrexone—Hyperhidrosis—Epirubicin—ovarian cancer	0.000134	0.000482	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—ovarian cancer	0.000133	0.000481	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—ovarian cancer	0.000133	0.000481	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—ovarian cancer	0.000133	0.000481	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—ovarian cancer	0.000133	0.000479	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000132	0.000478	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—ovarian cancer	0.000132	0.000475	CcSEcCtD
Naltrexone—Anorexia—Epirubicin—ovarian cancer	0.000132	0.000475	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—ovarian cancer	0.00013	0.000471	CcSEcCtD
Naltrexone—Vomiting—Docetaxel—ovarian cancer	0.00013	0.00047	CcSEcCtD
Naltrexone—Rash—Docetaxel—ovarian cancer	0.000129	0.000466	CcSEcCtD
Naltrexone—Dermatitis—Docetaxel—ovarian cancer	0.000129	0.000465	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—ovarian cancer	0.000129	0.000465	CcSEcCtD
Naltrexone—Headache—Docetaxel—ovarian cancer	0.000128	0.000463	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000128	0.000461	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—ovarian cancer	0.000128	0.000461	CcSEcCtD
Naltrexone—Infection—Doxorubicin—ovarian cancer	0.000127	0.000458	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000126	0.000454	CcSEcCtD
Naltrexone—Shock—Doxorubicin—ovarian cancer	0.000126	0.000454	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—ovarian cancer	0.000125	0.000452	CcSEcCtD
Naltrexone—Insomnia—Epirubicin—ovarian cancer	0.000125	0.000451	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—ovarian cancer	0.000125	0.00045	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—ovarian cancer	0.000124	0.000448	CcSEcCtD
Naltrexone—Paraesthesia—Epirubicin—ovarian cancer	0.000124	0.000448	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000124	0.000446	CcSEcCtD
Naltrexone—Dyspnoea—Epirubicin—ovarian cancer	0.000123	0.000444	CcSEcCtD
Naltrexone—Somnolence—Epirubicin—ovarian cancer	0.000123	0.000443	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—ovarian cancer	0.000122	0.00044	CcSEcCtD
Naltrexone—Nausea—Docetaxel—ovarian cancer	0.000122	0.000439	CcSEcCtD
Naltrexone—Decreased appetite—Epirubicin—ovarian cancer	0.00012	0.000433	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000119	0.00043	CcSEcCtD
Naltrexone—Fatigue—Epirubicin—ovarian cancer	0.000119	0.00043	CcSEcCtD
Naltrexone—Pain—Epirubicin—ovarian cancer	0.000118	0.000426	CcSEcCtD
Naltrexone—Constipation—Epirubicin—ovarian cancer	0.000118	0.000426	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000116	0.00042	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—ovarian cancer	0.000116	0.000417	CcSEcCtD
Naltrexone—Paraesthesia—Doxorubicin—ovarian cancer	0.000115	0.000414	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—ovarian cancer	0.000114	0.000411	CcSEcCtD
Naltrexone—Feeling abnormal—Epirubicin—ovarian cancer	0.000114	0.000411	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—ovarian cancer	0.000114	0.00041	CcSEcCtD
Naltrexone—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000113	0.000408	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—ovarian cancer	0.000111	0.000401	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00011	0.000398	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—ovarian cancer	0.00011	0.000398	CcSEcCtD
Naltrexone—Urticaria—Epirubicin—ovarian cancer	0.00011	0.000396	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—ovarian cancer	0.000109	0.000394	CcSEcCtD
Naltrexone—Pain—Doxorubicin—ovarian cancer	0.000109	0.000394	CcSEcCtD
Naltrexone—Abdominal pain—Epirubicin—ovarian cancer	0.000109	0.000394	CcSEcCtD
Naltrexone—Body temperature increased—Epirubicin—ovarian cancer	0.000109	0.000394	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—ovarian cancer	0.000105	0.00038	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000104	0.000377	CcSEcCtD
Naltrexone—Hypersensitivity—Epirubicin—ovarian cancer	0.000102	0.000367	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—ovarian cancer	0.000102	0.000366	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—ovarian cancer	0.000101	0.000365	CcSEcCtD
Naltrexone—Body temperature increased—Doxorubicin—ovarian cancer	0.000101	0.000365	CcSEcCtD
Naltrexone—Asthenia—Epirubicin—ovarian cancer	9.91e-05	0.000358	CcSEcCtD
Naltrexone—Pruritus—Epirubicin—ovarian cancer	9.77e-05	0.000353	CcSEcCtD
Naltrexone—Diarrhoea—Epirubicin—ovarian cancer	9.45e-05	0.000341	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—ovarian cancer	9.41e-05	0.00034	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—ovarian cancer	9.17e-05	0.000331	CcSEcCtD
Naltrexone—Dizziness—Epirubicin—ovarian cancer	9.13e-05	0.00033	CcSEcCtD
Naltrexone—Pruritus—Doxorubicin—ovarian cancer	9.04e-05	0.000326	CcSEcCtD
Naltrexone—Vomiting—Epirubicin—ovarian cancer	8.78e-05	0.000317	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—ovarian cancer	8.74e-05	0.000316	CcSEcCtD
Naltrexone—Rash—Epirubicin—ovarian cancer	8.71e-05	0.000314	CcSEcCtD
Naltrexone—Dermatitis—Epirubicin—ovarian cancer	8.7e-05	0.000314	CcSEcCtD
Naltrexone—Headache—Epirubicin—ovarian cancer	8.65e-05	0.000312	CcSEcCtD
Naltrexone—Dizziness—Doxorubicin—ovarian cancer	8.45e-05	0.000305	CcSEcCtD
Naltrexone—Nausea—Epirubicin—ovarian cancer	8.2e-05	0.000296	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—ovarian cancer	8.12e-05	0.000293	CcSEcCtD
Naltrexone—Rash—Doxorubicin—ovarian cancer	8.06e-05	0.000291	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—ovarian cancer	8.05e-05	0.000291	CcSEcCtD
Naltrexone—Headache—Doxorubicin—ovarian cancer	8e-05	0.000289	CcSEcCtD
Naltrexone—Nausea—Doxorubicin—ovarian cancer	7.59e-05	0.000274	CcSEcCtD
